Tilray Brands (NASDAQ:TLRY) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Tilray Brands (NASDAQ:TLRY) released its earnings results on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.16, FiscalAI reports. Tilray Brands had a negative return on equity of 10.39% and a negative net margin of 16.91%. The firm had revenue of $257.15 million for the quarter, compared to the consensus estimate of $266.26 million.

Here are the key takeaways from Tilray Brands’ conference call:

• Record Q1 results: Revenue rose 23% year over year to $257.1 million, gross profit increased 35% to $77.5 million, and consolidated gross margin expanded approximately 300 basis points to 30%. Management reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
• International cannabis remains a growth engine: EMEA revenue increased more than 70%, international cannabis revenue grew 21%, and Portugal and Germany are providing expanding EU-GMP capacity and lower-cost production. However, international price compression reduced cannabis profitability by approximately $8.8 million.
• BrewDog integration is showing early progress: Beverage revenue increased 82% to $101.5 million, largely due to BrewDog, which reached profitability in Q1 after cost reductions and restructuring. Management cited improving brand sales, 9,000 new distribution points, and plans to expand the brand internationally.
• New Carlsberg partnership adds scale: Beginning January 2027, Tilray will produce, market, sell, and distribute Carlsberg’s Elephant, 1664, and Kronenbourg 1664 Blanc brands in the U.S., potentially expanding revenue, manufacturing utilization, and distributor relationships.
• Profitability remains constrained by industry and financing headwinds: Tilray reported a $40 million GAAP net loss and $9.2 million of adjusted EBITDA, versus $10.2 million a year earlier, pressured by cannabis price compression, fuel surcharges, marketing investment, and $5 million of net cash interest expense. Canadian adult-use cannabis revenue also declined amid strain transitions, temporary supply constraints, and a shift toward higher-return international markets.

Tilray Brands Stock Down 2.7%

NASDAQ:TLRY traded down $0.09 during mid-day trading on Tuesday, hitting $3.27. The company’s stock had a trading volume of 4,057,972 shares, compared to its average volume of 4,235,954. Tilray Brands has a 1 year low of $3.25 and a 1 year high of $18.40. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.88 and a quick ratio of 1.11. The business’s fifty day moving average is $4.23 and its two-hundred day moving average is $4.96.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Portugal testing approval: Tilray Medical received approval from Portugal’s INFARMED regulator to conduct microbiological and chemical/physical quality testing in-house at its Cantanhede facility. The EU-GMP authorization could reduce reliance on third parties, shorten testing timelines, and accelerate product releases across regulated international medical-cannabis markets. The operational benefit is positive, although the announcement does not immediately change earnings. Tilray Medical Gains Approval for In-House Quality Testing at Portugal Facility
• Neutral Sentiment: BrewDog is supporting revenue growth: Coverage highlights increasing revenue from Tilray’s beer operations following the BrewDog acquisition. Management expects the beer assets and international cannabis business to remain growth drivers, but the acquisition-led growth has yet to translate into consistent profitability or positive free cash flow. BrewDog Acquisition Boosts Tilray’s Stock Q1 Performance
• Negative Sentiment: Core cannabis weakness: Analysts noted that fiscal first-quarter revenue growth was driven primarily by BrewDog, while cannabis revenue declined about 13%. This raises concerns about the performance of Tilray’s core business and the sustainability of its overall growth. Tilray Q1: Not Looking Good, Remains a Hold
• Negative Sentiment: Profitability and financing concerns: Recent commentary points to a net loss, an adjusted loss, approximately $23.4 million in cash burn, and share count growth of more than 31% year over year. The combination of negative cash flow and dilution is weighing on investor confidence and prompted at least one analyst to lower the price target. 3 Huge Red Flags From Tilray’s Q1 Earnings Report

Insider Activity

In other news, CFO Carl Merton bought 10,000 shares of the stock in a transaction dated Tuesday, August 4th. The shares were acquired at an average cost of $4.62 per share, with a total value of $46,200.00. Following the purchase, the chief financial officer directly owned 139,753 shares in the company, valued at $645,658.86. The trade was a 7.71% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have bought 15,000 shares of company stock worth $69,225. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TLRY shares. Weiss Ratings raised Tilray Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. Zacks Research downgraded Tilray Brands from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 29th. Canaccord Genuity Group lowered their price target on shares of Tilray Brands from $4.50 to $4.00 and set a “hold” rating on the stock in a report on Friday. Wall Street Zen lowered shares of Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Finally, ATB Cormark Capital Markets lowered their price target on shares of Tilray Brands from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.90.

Tilray Brands Company Profile

Tilray Brands, Inc is a global consumer packaged goods company focused on cannabis, beverage alcohol, wellness and consumer products. The company develops, produces, distributes and markets a range of cannabis products, including dried flower, pre-rolls, vapes, edibles and medical cannabis products, subject to applicable regulations in the markets it serves.

Tilray also operates beverage alcohol businesses, including craft beer, spirits and other alcoholic beverages. Its portfolio has included brands such as SweetWater Brewing Company, Montauk Brewing Company and Breckenridge Distillery.